Unlike common nutraceuticals stocked in every health store, CJC-1295 reaches researchers through a global research peptide market that Ōwani residents access almost entirely online. This matters because CJC-1295 quality ranges widely across the market — from analytically confirmed high-purity product to material with significant impurity issues — and the vendor is the entire quality system. Separating properly characterised CJC-1295 from the rest of the market requires three things: an HPLC chromatogram showing ≥98% purity, mass spec data verifying the correct molecular weight, and a batch-specific endotoxin panel. What follows is a practical research guide built specifically around CJC-1295, covering everything a Ōwani researcher needs before placing a first order.
The Science Behind CJC-1295
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Ōwani researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
Where to Buy CJC-1295 — A Researcher's Guide
Quality CJC-1295 sourcing begins with a simple filter: does this vendor make batch-matched COAs available before purchase? Vendors who do are operating transparently. When reviewing a CJC-1295 COA, verify: the batch number traces to your order, HPLC purity is ≥98%, mass spec identifies the correct molecular weight, and endotoxin levels are at acceptable levels for the intended application. Negative indicators in CJC-1295 vendor evaluation: prices far under typical market pricing, no information about manufacturing source, no community presence, and COAs that omit endotoxin testing. Keep lyophilised CJC-1295 at −20°C until ready to use; reconstitute only the quantity required for your immediate research and store the rest at −20°C.
Order CJC-1295 — ships to Ōwani
COA-verified · International tracking · Research grade
Research compound status for CJC-1295 means the safety evidence is drawn from animal studies, in-vitro work, and limited human observations — rather than the large-scale clinical data that informs approved drug safety. Proper handling of CJC-1295 requires careful sterile procedure — prep pad-cleaned septum, single-use needles, uncontaminated workspace — and cold chain maintenance from receipt through use. Verify the endotoxin level in your CJC-1295 batch COA before any protocol involving administration — look for results reported in endotoxin units per mg or mL and compare against acceptable research limits for your application. PubMed and bioRxiv are the primary literature resources for CJC-1295 research; favour indexed journal publications over preprints over case reports or anecdotal evidence.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
